The Germline and Somatic Origins of Prostate Cancer Heterogeneity
Authors:
- Takafumi N. YamaguchiTYTakafumi N. Yamaguchi
- Kathleen E. HoulahanKHKathleen E. Houlahan
- Helen ZhuHZHelen Zhu
- Natalie KurganovsNKNatalie Kurganovs
- Julie LivingstoneJLJulie Livingstone
- Natalie S. FoxNFNatalie S. Fox
- Jiapei YuanJYJiapei Yuan
- Jocelyn Sietsma PeningtonJPJocelyn Sietsma Penington
- Chol-Hee JungChol-Hee Jung
- Tommer SchwarzTSTommer Schwarz
- Weerachai JaratlerdsiriWJWeerachai Jaratlerdsiri
- Job van RietJRJob van Riet
Open Access
- 13 February 2025
- journal article
- biomarkers
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 15 (5) , 988-1017
Abstract
Newly diagnosed prostate cancers differ dramatically in mutational composition and lethality. The most accurate clinical predictor of lethality is tumor tissue architecture, quantified as tumor grade. To interrogate the evolutionary origins of prostate cancer heterogeneity, we analyzed 666 prostate tumor whole genomes. We identified a compendium of 223 recurrently mutated driver regions, most influencing downstream mutational processes and gene expression. We identified and validated individual germline variants that predispose tumors to acquire specific somatic driver mutations: these explain heterogeneity in disease presentation and ancestry differences. High-grade tumors have a superset of the drivers in lower-grade tumors, including increased frequency of BRCA2 and MYC mutations. Grade-associated driver mutations occur early in tumor evolution, and their earlier occurrence strongly predicts cancer relapse and metastasis. Our data suggest high- and low-grade prostate tumors both emerge from a common premalignant field, influenced by germline genomic context and stochastic mutation timing. Significance: This study uncovered 223 recurrently mutated driver regions using the largest cohort of prostate tumors to date. It reveals associations between germline SNPs, somatic drivers, and tumor aggression, offering significant insights into how prostate tumor evolution is shaped by germline factors and the timing of somatic mutations.Keywords
All Related Versions
Funding Information
- National Cancer Institute (R01CA270108)
- National Cancer Institute (U2CACA271894)
- DOD Prostate Cancer Research Program (W81XWH2210247)
- DOD Prostate Cancer Research Program (W81XWH2210751)
This publication has 151 references indexed in Scilit:
- Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing NationJournal of Clinical Oncology, 2009
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- g:Profiler—a web-based toolset for functional profiling of gene lists from large-scale experimentsNucleic Acids Research, 2007
- Gene expression profiling identifies clinically relevant subtypes of prostate cancerProceedings of the National Academy of Sciences, 2004
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003
- The Structure of Haplotype Blocks in the Human GenomeScience, 2002
- Gene expression correlates of clinical prostate cancer behaviorCancer Cell, 2002
- dbSNP: the NCBI database of genetic variationNucleic Acids Research, 2001
- Environmental and Heritable Factors in the Causation of Cancer — Analyses of Cohorts of Twins from Sweden, Denmark, and FinlandNew England Journal of Medicine, 2000
- Pretreatment Nomogram for Prostate-Specific Antigen Recurrence After Radical Prostatectomy or External-Beam Radiation Therapy for Clinically Localized Prostate CancerJournal of Clinical Oncology, 1999